Moderna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
MarketWatch· Jaimy Lee· Oct 22, 2026 · 8:14 PM
A ‘sell-the-news reaction’? The experimental treatment helped prevent the return of cancer or death in melanoma patients by 42% after two years.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 4 hours ago
Micron’s stock is dirt cheap — and that’s igniting a fierce online debate
Valuation purists see a ridiculously inexpensive stock, but some semiconductor investors say Micron’s earnings power won’t hold up.
MarketWatch
marketsabout 4 hours ago
A disturbing employment trend is hiding beneath the latest strong job numbers
The average jobless worker's bout of unemployment surpassed 27 weeks in October, the highest outside of the pandemic period in a decade.
CNBC Markets
marketsabout 6 hours ago
My adviser recommended an annuity. Is it the right move in this market environment?
“I haven’t committed to the strategy yet and would appreciate some independent perspectives.”
MarketWatch